---
title: Intra-Abdominal Infections
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[Huppert's Notes]]

# Intra-Abdominal Infections #ğŸš§ æ–½å·¥ä¸­

### Intra-Abdominal Infections

##### Peritonitis/intra-abdominal abscess

â€¢Â Â Â Pathogenesis: Disruption of or inflammation in the GI tract may allow normal bowel flora to enter the abdominal cavity and cause frank peritonitis and/or the development of intra-abdominal abscesses

â€¢Â Â Â Pathogens:

-Â Â Â These infections are almost always polymicrobial

-Â Â Â Colonic organisms are the predominant pathogens, which include: *E. coli, Klebsiella* spp., *Proteus* spp., *Enterobacter* spp., *Enterococcus* spp., anaerobic organisms, such as *B. fragilis*

â€¢Â Â Â Clinical features:

-Â Â Â Abdominal pain, nausea, vomiting, or bloating \+/â€“ fever, tachycardia, hypotension. Some patients may appear relatively stable, while others may have florid shock

-Â Â Â Patients age 65\+ yr, immunocompromised, or those on chronic steroids may have especially occult presentations of severe intra-abdominal infections with less pronounced pain

â€¢Â Â Â Diagnosis:

-Â Â Â If unstable, consult general surgery to determine the need for immediate surgical intervention vs. whether to first obtain diagnostic imaging studies (typically CT abdomen/pelvis with contrast)

â€¢Â Â Â Treatment:

-Â Â Â Procedural interventions: Surgical intervention or percutaneous drainage are key aspects of management for complicated intra-abdominal infection. Consult general surgery and/or interventional radiology. Obtain cultures from drained material to guide antimicrobial management

-Â Â Â Antibiotic therapy:

**â€¢**Â Â Â Start antibiotics ASAP to cover enteric Gram-positive, Gram-negative, and anerobic organisms

**â€¢**Â Â Â Patients with certain risk factors are considered high-risk (age >70 yr, diffuse peritonitis, severe sepsis, immunocompromising conditions, health careâ€“acquired infections) and warrant coverage of multidrug-resistant (MDR) organisms

**â€¢**Â Â Â Regimens include:

-Â Â Â Low-risk community acquired infections:

â€¢Â Â Â Ertapenem

â€¢Â Â Â Ciprofloxacin or ceftriaxone \+ metronidazole

-Â Â Â High-risk community acquired infections or hospital-acquired infections:

â€¢Â Â Â Piperacillin-tazobactam

â€¢Â Â Â Meropenem

â€¢Â Â Â Cefepime \+ metronidazole

##### ***Clostridium difficile***

â€¢Â Â Â Pathophysiology:

-Â Â Â *C. difficile* colitis can occur as a result of either community-acquired or nosocomial infections

-Â Â Â Not all strains of *C. difficile* cause infection; only toxin producing strains cause diarrhea and colitis.

-Â Â Â Risk factors for *C. difficile* infection include:

**â€¢**Â Â Â Recent antibiotic use (commonly implicated antibiotics include clindamycin, fluoroquinolones, and cephalosporins)

**â€¢**Â Â Â Age â‰¥65 yr

**â€¢**Â Â Â Suppression of gastric acid with PPIs or H2-blockers is also associated with an increased risk of *C. difficile* infection, though the exact mechanism for this is unknown

â€¢Â Â Â Clinical features:

-Â Â Â Range from mild diarrheal illness to a severe, fulminant, and potentially fatal colitis

-Â Â Â Criteria for severe *C. difficile* infection:

**â€¢**Â Â Â More frequent diarrhea and more severe abdominal pain

**â€¢**Â Â Â Very high leukocytosis, often â‰¥15K cells/Î¼L

**â€¢**Â Â Â Hypotension and lactic acidosis due to hypovolemia and sepsis

**â€¢**Â Â Â AKI with Cr â‰¥1.5 mg/dL

**â€¢**Â Â Â Colonic ileus with little to no diarrhea, which is known as â€œtoxic megacolonâ€

â€¢Â Â Â Diagnosis:

-Â Â Â Perform *C. difficile* stool testing in patients with a diarrheal illness (e.g., â‰¥3 watery stools in a day) and no alternative reason to have loose stools (e.g., laxative use)

-Â Â Â Consider CT abdomen/pelvis if concern for severe or fulminant disease

â€¢Â Â Â Treatment:

-Â Â Â First-line treatment: Vancomycin 125 mg PO QID Ã—10 days or fidaxomicin 200 mg PO BID Ã—10 days. Add metronidazole 500 mg IV TID only if fulminant disease.

-Â Â Â Recurrent disease: Defined by resolution of symptoms with therapy followed by return of symptoms within 2 months of treatment completion. Requires longer course of antibiotics.

